HIV management: New approaches

Current Drug Therapy

Volumn 2, Issue 2, 2007, Pages 111-119

  Shidhaye, Supriya S ^a   Hemant, Pagar ^a   Majid, Haddadi ^a   Kadam, Vilasrao ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

HIV management; Non nucleoside reverse transcriptase inhibitors (NNRTIs); Nucleoside reverse transcriptase inhibitors (NRTIs); Protease; Protease inhibitors (PIs); Reverse transcriptase

Indexed keywords

2' DEOXY 3' OXA 4' THIOCYTIDINE; 3' FLUOROTHYMIDINE; ABACAVIR; AMDOXOVIR; AVX 754; BETA DEXTRO 2,6 GUANOSINE; CALANOLIDE A; CP 94707; DAPIVIRINE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVUCITABINE; EMTRICITABINE; ENVELOPE PROTEIN; ETRAVIRINE; GAG PROTEIN; LAMIVUDINE; NEVIRAPINE; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; LIVER DISEASE; LIVER TOXICITY; MOLECULAR MECHANICS; NAUSEA; PRIORITY JOURNAL; REVIEW; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; STOMACH DISCOMFORT; STRUCTURE ANALYSIS; VOMITING;

EID: 34249317631     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488507780619031     Document Type: Review

References (88)

1. Gallo RC, Sarin PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220: 865-7.
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
3. source www.UNAIDS.org et al.
4. Clavel F, Guetard D, Brun-Vezinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233: 343-6.
5. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288: 1789-96.
6. Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet 2004; 5: 52-61.
7. David L, Nelson, Michael M Cox. Principles of Biochemistry, fourth Edition, New York, Freeman WH and Company. 2005; 1022-4.
8. Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998; 251: 1-15.
9. Freed EO. HIV-1 replication. Somat Cell Mol Genet 2001; 26:13-33.
10. Ferguson MR, Rojo DR, von Lindern JJ, O'Brien WA. HIV-1 replication cycle. Clin Lab Med 2002; 22: 611-35.
11. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T59 lymphotropic virus type III/ Lymphadenopathy -associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-100.
12. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35.
13. Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 2002; 23: 381-88.
14. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-4.
15. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-6.
16. De Mendoza C, Soriano V. Resistance to HIV protease inhibitors: mechanisms and clinical consequences. Curr Drug Metab 2004; 5: 321-8.
17. http:/www.iasusa.org/resistance_mutations/index.html.
18. Descamps D, Flandre P, Calvez V. et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000; 283: 205-11.
19. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283: 229-34.
20. Maguire M, Gartland M, Moore S, et al. Absence of zidovudine resistance in antiretroviral-naïve patients following Zidovudine/ Lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000; 14: 1195-201.
21. Gallego O, Ruiz L, Vallejo A, et al. Changes in the rate of geno-typic resistance to antiretroviral drugs in Spain. AIDS 2001; 15: 1894-96.
22. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-46.
23. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type I: 2003 recommendations of the International AIDS Society-USA panel. Clin Infect Dis 2003; 37: 113-28.
24. Vora S, Marcelin AG, Gunthard H, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in PI-experienced patients. Antivir Ther 2005; 10: S9.
25. Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 2005; 79: 3329-38.
26. Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004; 18: 1965-66.
27. Kagan RM, Shenderovich MD, Heseltine PN, Ramnarayan K. Structural analysis of an HIV-1 protease 147A mutant resistant to the protease inhibitor lopinavir. Protein Sci 2005; 14: 1870-8.
28. Boehringer Ingelheim. Aptivus [package insert]. Germany: Boehringer Ingelheim. 2005.
29. Stanfield-Oakley SA, Mosier SM, Davison DK, et al. Impact of Mutations in HR2 of HIV-1 env gp41 on susceptibility to enfuvirtide. Antivir Ther 2005; 10: S75.
30. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 2000; 283: 381-90.
31. Carr A, Chuah J, Hudson J, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo 1 study. AIDS 2000; 14: 1171-80.
32. Katz RA, Skalka AM. The retroviral enzymes. Annu Rev Biochem 1994; 63: 133-73.
33. Arts EJ, Marois JP, Gu Z, Le Grice SFJ, Wainberg MA. Effects of 39-deoxynucleotide 59- triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type-1 reverse transcription of minus- strand strong-stop DNA. J Virol 1996; 70: 712-20.
34. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 29,39-dideoxyinosine and 29,39-dideoxycytidine. J Virol 1992; 66: 7128-35.
35. Kim EY, Vrang L, Oberg B, Merigan TC. Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants. AIDS Res Hum Retroviruses 2001; 17: 401-407.
36. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 39-fluoro-39-deoxythymidine. Antimicrob Agents Chemother 1992; 36: 808-18.
37. Pan XZ, Qui ZD, Baron PA, et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by 39-fluoro-39- deoxythymidine, recombinant soluble CD4 and recombinant interferon-alpha. AIDS Res Hum Retroviruses 1992; 8: 589-95.
38. Lundgren B, Bottiger D, Ljungdahl-Stahle E, et al. Antiviral effects of 39 fluorothymidine and 39-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J AIDS 1991; 4: 489-98.
39. Barditch-Crovo PA, Kornhauser DM, Petty BG, et al. Phase I phamacokinetic evaluation of 39-deoxy-39-fluorothymidine (FLT), a new potent anti HIV nucleoside [abstract 2114]. VIIth International Conference on AIDS Florence, Italy. Rome 1991; 210.
40. Katlama C, Ghosn J, Tubiana R, et al. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study. AIDS 2004; 18: 1299-304.
41. Schinazi RF, Mellors JW, Bazmi HZ, et al. DPC-817: a cytidine nucleoside analog with activity against zidovudineand lamivudine-resistant viral variants. Antimicrob Agents Chemother 2002; 46: 1394-401.
42. Stuyver LJ, McBrayer TR, Schürmann D, et al. Potent antiviral effect of Reverset™ in HIV-1 infected adults following a single oral dose. Antivir Ther 2004; 9: 529-36.
43. Ma L, Hurwitz SJ, McAtee JJ, et al. Pharmacokinetics of the anti-viral agent -D-2,3- didehydro-2,3-dideoxy-5- fluorocytidine in rhesus monkeys. Antimicrob Agents Chemother 43: 381-4.
44. Blaney SM, Daniel MJ, Harker AJ, Godwin K, Balis FM. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob Agents Chemother 1995; 39: 2779-82.
45. Qian M, Finco TS, Metha M, Viswanathan CT, Gallo J. Pharmacokinetic evaluation of drug interactions with zidovudine: probenecid and zidovudine in monkeys. J Pharm Sci 1991; 80: 1007-11.
46. Richard N, Salomon H, Rando R, et al. Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′-oxa4′-thio-5-fluorocytidine. Antimicrob Agents Chemother 2000; 44: 1127-31.
47. De Muys J-M, Gourdeau H, Nguyen-Ba N, et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa4′-thiacytidine. Antimicrob Agents Chemother 1999; 43: 1835-44.
48. Dunkle LM, Gathe JC, Pedevillano DE, et al. Elvucitabine: potent antiviral activity demonstrated in multi-drug resistant HIV infection. Antivir Ther 2003; 8: S5.
49. Bethell R, Adams J, De Muys J, et al. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754 [Abstract A-508] 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA 2004.
50. Furman PA, Jeffrey J, Kiefer LL, et al. Mechanism of action of 1-ß-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-ß-D-dioxolane guanosine. Antimicrob Agents Chemother 2001; 45: 158-65.
51. Bazmi HZ, Hammond JL, Cavalcanti SC, et al. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)ß-D-dioxolane-guanosine and suppress resistance to 3′-azido- 3′-deoxythymidine. Antimicrob Agents Chemother 2000; 44: 1783-8.
52. Mewshaw JP, Myrick FT, Wakefield DACS, et al. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients from whom standard nucleoside therapy fails. J Acquir Immune Defic Syndr 2002; 29: 11-20.
53. Winters MA, Coolley KL, Girard YA, et al. A 6-basepair insert in the reverse transcriptase gene of human immuno deficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102: 1769-75.
54. Jeffrey JL, Feng JY, Qi CCR, Anderson KS, Furman PA. Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase - steady state and pre-steady state kinetic analyses. J Biol Chem 2003; 278: 18971-9.
55. Lennerstrand J, Hassani Espili N, Pavlova A, et al. Effects of M184V mutation in multi- dideoxynucleoside analog resistant HTV-1 reverse transcriptase on removal of ß-D-dioxolane- guanine monophosphate from blocked primer. Antivir Ther 2005; 10: S79.
56. Schinazi RF, Asif G, Detorio M, et al. 1-(ß-D-Dioxolane)thymidine (DOT) is a TK-dependent orally bioavailable nucleoside with specific activity against HIV-1 resistant variants. Antivir Ther 2005; 10: S65.
57. Uckun FM, Pendergrass S, Venkatachalam TK, Qazi S, Richman DD. Stampidine is a potent inhibitor of zidovudine and nucleoside analog reverse transcriptase inhibitor resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 2002; 46: 3613-6.
58. Kodama EI, Kohgo S, Kitano K, et al. 4′-Ethynyl nucleoside analogs: potent inhibitors of multi drug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 2001; 45: 1539-46.
59. Deval J, Selmi B, Boretto J, et al. The molecular mechanism of multidrug resistance by the Q151M human immuno deficiency virus type 1 reverse transcriptase and its suppression using á-boranophosphate nucleotide analogues. J Biol Chem 2002; 277: 42097-104.
60. Matamoros T, Deval J, Guerreiro C, Mulard L, Canard B, Menéndez-Arias L. Suppression of multi-drug-resistant HIV-1 reverse transcriptase primer unblocking activity by α-phosphate- modified thymidine analogues. J Mol Biol 2005; 349: 451-63.
61. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005; 88: 209-31.
62. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleosides reverse transcriptase inhibitor binding. Curr HIV Res 2004; 2: 323-32.
63. Erickson JW, Burt SK. Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol 1996; 36: 545-571.
64. De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazol [4,5,1 jk] (1,4) benzodiazepine -2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2005; 48: 1689-96.
65. Temiz NA, Bahar I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 2002; 49: 61-70.
66. Udier-Blagovic M, Tirado-Rives J, Jorgensen WL. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J Am Chem Soc 2003; 125: 6016-7.
67. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-6.
68. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC125: a new, next -generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17: 49-54.
69. Janssen PAJ, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile <278474, Rilpivirine). J Med Chem 2005; 48:1901-9.
70. Pata JD, Stirtan WG, Goldstein SW, Steitz TA. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 2004; 101: 10548-53.
71. Gao Q, Wang L, Liang TX. Total Synthesis of (±)-Inophyllum B. Chin Chem Lett 2002; 13(8): 714-6.
72. Wlodawer R, Erickson JW. Annu Rev Biochem 1993; 62: 543.
73. Chow YK. Nature 1993; 361: 650.
74. Larder BA, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inbibitor-resistant HIV-1 clinical samples. AIDS 2000; 4: 1943-8.
75. Rusconi S, La Seta Catamancio S, Citterio, P, et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000; 44: 1328-32.
76. Kohlbrenner VM, Hall DB, Schapiro J, et al. Development of a tipranavir mutation score: analysis of protease mutations associated with phenotypic drug susceptibility and antiviral response in Phase II clinical trials. Antivir Ther 2004; 9: S143.
77. Mehandru S, Markowitz M. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs 2003; 12: 1821-8.
78. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47: 3123-9.
79. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314-21.
80. King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004; 78: 12012-21.
81. Surleraux DLNG, Tahri A, Verschueren WG, et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005; 48: 1813-22.
82. Peeters M, Van Baelen B, De Meyer S, et al. TMC114/RTV activity in multiple PI-experienced patients: correlation of baseline genotype, phenotype, pharmacokinetics, and IQ with antiviral activity at day 14 [Abstract 5331. 11th Conference on Retroviruses and Opportunistic Infections 2004, San Francisco, USA.
83. Arasteh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inbibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS 2005; 19: 943-7.
84. www.clinicaltrial.gov
85. www.pharma.org
86. www.innovation.org
87. www.pparx.org
88. www.buysafedrugs.info